DalCor Pharmaceuticals

CARDIOVASCULAR DISEASES The Leading Cause of Death Worldwide Cardiovascular disease (CVD) is the leading cause of death globally, accounting for 25% of deaths in the U.S. and 31% of deaths worldwide. Nearly 18 million people die each year from cardiovascular disease (CVD)-related events including myocardial infarction (MI). Despite current standard of care treatments, residual risk […]

DAL-GENE TRIAL dal-GenE Clinical Trial DalCor completed the dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This trial was initiated to determine the ability of dalcetrapib to reduce cardiovascular (CV) morbidity and mortality in a population experiencing an acute coronary syndrome (ACS) within 1-3 months before randomization (N=6147) and identified as carrying the […]

DAL-GENE-2 TRIAL Dal-GenE-2 Clinical Trial Dal-GenE-2 (Dal-302), a phase III, double-blind, randomized placebo-controlled study, will evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal MI in 2,000 patients with a documented recent acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene. The study will be […]

Dalcetrapib History Improving Cardiovascular Outcomes with Precision Medicine Dalcetrapib is an investigational therapy that would potentially be the first pharmacogenomic precision medicine in cardiovascular disease to reduce cardiovascular risk. Dalcetrapib, while under development by Roche, was evaluated in a Phase 3, double- blind clinical trial, dal-OUTCOMES. The dal-OUTCOMES trial randomized over 15,000 patients with recent acute […]

PUBLICATIONS Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial J.-C. Tardif et al.European Heart JournalJuly 2022 VIEW PUBLICATION Inhibition of the 3CL Protease and SARS-CoV‑2 Replication by Dalcetrapib E. Niesor, G. Boivin, E. Rhéaume, et al.ACS OmegaJune 2021 VIEW PUBLICATION Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib D. […]

BOARD OF DIRECTORS PAUL R. FONTEYNE CHAIRMAN With more than 30 years of global pharmaceutical experience, Paul Fonteyne’s career spans over three decades of leadership roles across North America and Europe with companies including Boehringer-Ingelheim, Merck, and Abbott Laboratories. Until 2018, he was President and CEO, Boehringer-Ingelheim USA. He is past board member of the […]

CONSEIL D’ADMINISTRATION PAUL R. FONTEYNE PRÉSIDENT Avec plus de 30 ans d’expérience pharmaceutique mondiale, la carrière de Paul Fonteyne s’étend sur plus de trois décennies, durant lesquelles il a occupé des postes de direction en Amérique du Nord et en Europe au sein de sociétés telles que Boehringer-Ingelheim, Merck et Abbott Laboratories. Jusqu’en 2018, il […]

GESTION FOUZIA LAGHRISSI-THODE, M.D. PRÉSIDENTE-DIRECTRICE GÉNÉRALE Fouzia Laghrissi-Thode a été nommée présidente-directrice générale de DalCor Pharmaceutiques en avril 2018. Plus récemment, la Dre Laghrissi-Thode était vice-présidente chez AstraZeneca responsable de la franchise cardiorénale aux Etats-Unis. Dans ses fonctions précédentes, elle a dirigé la stratégie mondiale de produits et du portefeuille dans les domaines thérapeutiques des […]

MANAGEMENT FOUZIA LAGHRISSI-THODE, M.D. CHIEF EXECUTIVE OFFICER Fouzia Laghrissi-Thode, was appointed as Chief Executive Officer of DalCor Pharmaceuticals in April 2018. Most recently, Dr. Laghrissi-Thode was Vice-President at AstraZeneca of the US Renal-Cardiology Therapeutic Area. In her previous roles she led the global product and portfolio strategy of the cardiovascular, metabolism and renal therapeutic areas […]

À PROPOS DE DALCOR Pionnier en médecine de précision pour le traitement des maladies cardiovasculaires DalCor Pharmaceutiques est une société biopharmaceutique axée sur la lutte contre les maladies cardiovasculaires, le plus grand fardeau mondial en matière de santé. Notre objectif est de fournir dalcetrapib, le premier médicament pharmacogénétique de précision contre les maladies cardiovasculaires qui […]

ABOUT DALCOR Pioneering Precision Medicine for Cardiovascular Disease DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene (ADCY9 AA […]

Les partenaires

PARTNERS

DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.

Dalcor Pharma discusses its business strategy and innovations in a BFM Business interview. The company highlights its focus on developing specialized pharmaceutical solutions for rare diseases. Key topics include research advancements and partnerships driving progress in therapeutic areas.

Dec 2024DalCor PharmaceuticalsNews article

DalCor Pharmaceuticals secures **$80 million in Series D funding** to advance a **confirmatory trial** for its CETP inhibitor drug candidate. The company receives **FDA approval** for the study, which will employ a **biomarker strategy** following earlier setbacks with dalcetrapib. The trial aims to reassess cardiovascular disease treatment potential after prior mixed results.

Sep 2023genomeweb.comNews article

DalCor Pharmaceuticals initiates the **Dal-GenE-2 confirmatory trial** for its gene therapy program. The company also finalizes a **Series D financing round**, securing additional capital to advance development efforts. The trial and funding mark key milestones in the biotech firm’s pipeline progression.

Sep 2023GlobeNewswireNews article

DalCor Pharmaceuticals publishes dal-GenE Phase 3 trial results in the *European Heart Journal*, evaluating pharmacogenetics-guided dalcetrapib therapy for patients after an acute coronary syndrome. The study assesses precision medicine outcomes in cardiovascular treatment, marking a key milestone in personalized drug response research.

Jul 2022BioSpaceNews article